| ||Lab Test|
| Test Description|
|LIS Test Code:||CATN1|
|Lab Area:||Mayo Medical Labs|
| Specimen Collection|
|Container:||Red/Yellow Rim 4mL SST |
|Delivery Instructions:||Send specimen to 2C324 or Tube Station 321|
|Specimen Type: ||Blood|
|Frequency / Restrictions: |
| Expected Values/Results|
Ranges and Interpretation:
Calcitonin pg/mL (SI: ng/L = 1.0 x pg/mL)
Performed at Mayo Medical Labs, Rochester MN
Effective 19Jun02 - present:
Male: 0 - 15.9
Female: 0 - 7.9
PEAK CALCIUM INFUSION:
Male: 0 - 130
Female: 0 - 90
For <=16 years reference ranges are not established.
|Organisms Reported: |
| Additional Test Information|
In the normal physiological situation, calcitonin is a polypeptide hormone
secreted by the parafollicular cells (also referred to as calcitonin cells or
C-cells) of the thyroid gland. The main action of calcitonin is the inhibition
of bone resorption by regulating the number and activity of osteoclasts.
Calcitonin is secreted in direct response to serum hypercalcemia and may prevent
large oscillations in serum calcium levels and excessive loss of body calcium.
However, in comparison to parathyroid hormone and 1,25-dihydroxyvitamin D, the
role of calcitonin in the regulation of serum calcium in humans is minor.
Measurements of serum calcitonin levels are, therefore, not useful in the
diagnosis of disorders of calcium homeostasis.
Malignant tumors arising from thyroid C-cells (medullary thyroid carcinoma:
MTC) usually produce elevated levels of calcitonin. MTC is an uncommon malignant
thyroid tumor, comprising <5% of all thyroid malignancies. Approximately 25%
of these cases are familial, usually appearing as a component of multiple
endocrine neoplasia type II (MENII, Sipple syndrome). MTC may also occur in
families without other associated endocrine dysfunction, with similar autosomal
dominant transmission as MENII, which is then called familial medullary thyroid
carcinoma (FMTC). Mutations in the RET
proto-oncogene are associated with MENII and FMTC.
Other neuroectodermal endocrine tumors, particularly islet cell tumors, may
also produce calcitonin, but do so much less frequently. Calcitonin elevations
also may occur with:
-Cancer of the lung, breast, or pancreas
-Intestinal, gastric, or bronchial carcinoids
-Chronic renal failure, Zollinger-Ellison syndrome, or pernicious anemia
-Pregnant females at term
Starting June 13, 2005: Automated Immunochemiluminometric Assay (ICMA – DPC)
Starting June 19, 2002: Two-site Chemiluminescence Immunoassay. Automated Immunochemiluminometric Assay (ICMA – Nichols Diagnostics)
Before June 19, 2002: Radioimmunoassay (RIA) after Cartridge Extraction.
This test is not useful for evaluating calcium metabolic diseases.
Falsely elevated values may occur in serum from patients who have developed
human antimouse antibodies or heterophilic antibodies.
Values obtained with different assay methods or kits may be different and
cannot be used interchangeably. Test results cannot be interpreted as absolute
evidence for the presence or absence of malignant disease.
|Archived Ranges:||Historical Reference Ranges|